Keywords
Hypernatremia
predictive value
deceased patients
How to Cite
Abstract
Introduction: Angiotensin II converting enzyme is the receptor used by SARS-CoV2 to enter cells and its blockagecan affect the regulation of fluid and electrolyte balance, generating several alterations, including hypernatremia. Objective: Since an increase in plasma sodium has been reported as a negative prognostic factor in hospitalized patients with COVID-19, we decided to evaluate its predictive value at the Hospital de alta complejidad del Bicentenario Esteban Echeverría, Buenos Aires, Argentina. Materials and methods: By using the laboratory database, plasma sodium levels were retrospectively analyzed in a cohort of 160 patients during the first semester of 2021. Results: Deceased patients (N=98) showed a significant increase in plasma sodium after 48 hours of hospitalization (p<0.01), which was not observed in non-deceased patients (N=62). When comparing the levels of plasma sodium on the fifth day of hospitalization, significant differences (p<0.0001) were observed between both groups. For each age range, the percentage of deaths in patients with hypernatremia was higher than that in the total hospitalized patients. The percentage of deaths increased according to the age and hypernatremia degree. Conclusion: The probability that patients die if they present high sodium values within the first days of hospitalization is high and increases with the age and degree of hypernatremia, demonstrating the high predictive value of this marker in deceased patients with COVID-19.
References
Sjöström A, Rysz S, Sjöström H, Höybye C. Hypernatremia is common in patients with severe COVID-19 and indicates a poor prognosis. [preprint]. 2020. Available from: https://www.researchsquare.com/article/rs-81965/v1.
https://doi.org/10.21203/rs.3.rs-81965/v1
Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensinaldosterone inhibitors. Eur Heart J. 2020; 41:1810-1817. https://doi.org/10.1093/eurheartj/ehaa373
Lindner G, Funk GC, Schwarz C, Kneidinger N, Kaider A, Schneeweiss B, Kramer L et al. Hypernatremia in the critically ill is an independent risk factor for mortality. Am J Kidney Dis. 2007;50(6):952-957.
https://doi.org/10.1053/j.ajkd.2007.08.016
Wolf J, Possebon Berlesi F, Crestani dos Santos T, Barreto Glaeser A, Lunge V, Gasparetto Maccari J. et al. Hypernatremia increases mortality in patients admitted by COVID-19: A Retrospective longitudinal study with 1000 patients. [preprint]. 2022. Available from: https://www.researchsquare. com/article/rs-1361819/v1.
https://doi.org/10.21203/rs.3.rs-1361819/v1
Zimmer MA, Zink AK, Weißer CW, Vogt U, Michelsen A, Priebe HJ et al. Hypernatremia- A Manifestation of COVID-19: A Case Series. A A Pract. 2020; 14(9):e01295. https://doi.org/10.1213/XAA.0000000000001295
Tzoulis P, Waung JA, Bagkeris E, Hussein Z, Biddanda A, Cousins J et al. Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19. J Clin Endocrinol Metab. 2021; 13;106(6):1637-1648.